1-20 of 25
polycythemia vera
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

Aaron T. Gerds
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 407–414.
https://doi.org/10.1182/hematology.2019000048
Published: 2019
Journal Articles

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Alessandro M. Vannucchi, Paola Guglielmelli
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 480–488.
https://doi.org/10.1182/asheducation-2017.1.480
Published: 2017
Journal Articles

Update from the latest WHO classification of MPNs: a user’s manual

Francesco Passamonti, Margherita Maffioli
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 534–542.
https://doi.org/10.1182/asheducation-2016.1.534
Published: 2016
Journal Articles

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Deepti Radia, Holly L. Geyer
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 340–348.
https://doi.org/10.1182/asheducation-2015.1.340
Published: 2015
Journal Articles

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Naveen Pemmaraju, Ruben Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 649–651.
https://doi.org/10.1182/asheducation-2015.1.649
Published: 2015
Journal Articles

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer, Ruben A. Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 277–286.
https://doi.org/10.1182/asheducation-2014.1.277
Published: 2014
Journal Articles

Management of MPN beyond JAK2

Claire N. Harrison, Natalia Curto Garcia
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 348–354.
https://doi.org/10.1182/asheducation-2014.1.348
Published: 2014
Journal Articles

The spectrum of JAK2-positive myeloproliferative neoplasms

Jean-Jacques Kiladjian
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 561–566.
https://doi.org/10.1182/asheducation.V2012.1.561.3807838
Published: 2012
Journal Articles

Thrombotic disease in the myeloproliferative neoplasms

Anna Falanga, Marina Marchetti
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 571–581.
https://doi.org/10.1182/asheducation.V2012.1.571.3798557
Published: 2012
Journal Articles

Management of Myelofibrosis

Alessandro M. Vannucchi
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 222–230.
https://doi.org/10.1182/asheducation-2011.1.222
Published: 2011
Journal Articles

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants

James Vardiman, Elizabeth Hyjek
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 250–256.
https://doi.org/10.1182/asheducation-2011.1.250
Published: 2011
Journal Articles

Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera

Claire Harrison
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 129–134.
https://doi.org/10.1182/asheducation-2010.1.129
Published: 2010
Journal Articles

Assessing New Therapies and Their Overall Impact in Myelofibrosis

Ruben A. Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 115–121.
https://doi.org/10.1182/asheducation-2010.1.115
Published: 2010
Journal Articles

Pathogenesis and management of essential thrombocythemia

Philip A. Beer, Anthony R. Green
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 621–628.
https://doi.org/10.1182/asheducation-2009.1.621
Published: 2009
Journal Articles

Therapeutic potential of JAK2 inhibitors

Srdan Verstovsek
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 636–642.
https://doi.org/10.1182/asheducation-2009.1.636
Published: 2009
Journal Articles

New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia

Ross L. Levine, Mark Heaney
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 76–82.
https://doi.org/10.1182/asheducation-2008.1.76
Published: 2008
Journal Articles

The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?

Chloé James
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 69–75.
https://doi.org/10.1182/asheducation-2008.1.69
Published: 2008
Journal Articles

Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders

Ruben A. Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 355–362.
https://doi.org/10.1182/asheducation-2007.1.355
Published: 2007
Journal Articles

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders

Ross L. Levine, Gerlinde Wernig
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 233–239.
https://doi.org/10.1182/asheducation-2006.1.233
Published: 2006
Journal Articles

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2 V617F Era

Ayalew Tefferi
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 240–245.
https://doi.org/10.1182/asheducation-2006.1.240
Published: 2006